Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -5.10% is 5985% below its 5-year average of 0.09%, around the middle of its 5-year range (-18.18%–19.40%).
As of the fiscal period ended Tuesday, September 30, 2025. 20.28% below its 12-month average of -4.24%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-09-30.
RETURN ON EQUITY (ROE)
-5.10%
RETURN ON EQUITY (ROE) AVG TTM
-4.24%
RETURN ON EQUITY (ROE) AVG 3Y
-6.16%
RETURN ON EQUITY (ROE) AVG 5Y
0.09%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-20.28%
CURRENT VS 3Y AVG
+17.17%
CURRENT VS 5Y AVG
-5984.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+87.86%
vs the sector median at left
BGM Group Ltd.
Market Cap
$122.43M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$122.66M
Return on Equity (ROE)
-71.83%
TTM Avg
-71.89%
3Y Avg
-76.88%
5Y Avg
-67.88%
Market Cap
$124.18M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$120.58M
Return on Equity (ROE)
-2.13%
TTM Avg
-45.09%
3Y Avg
-61.80%
5Y Avg
-44.27%
Market Cap
$120.41M
Return on Equity (ROE)
-30.12%
TTM Avg
-27.41%
3Y Avg
-24.34%
5Y Avg
-19.85%
Market Cap
$124.70M
Return on Equity (ROE)
-234.42%
TTM Avg
-102.69%
3Y Avg
-100.55%
5Y Avg
-100.92%
Market Cap
$119.84M
Return on Equity (ROE)
-663.38%
TTM Avg
-427.48%
3Y Avg
-294.92%
5Y Avg
-251.31%
Market Cap
$118.83M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
Market Cap
$118.59M
Return on Equity (ROE)
-148.56%
TTM Avg
-96.59%
3Y Avg
-83.25%
5Y Avg
-64.44%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BGM Group Ltd. (BGM) | $122.43M | -5.10% | -4.24% | -6.16% | 0.09% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | -71.83% | -71.89% | -76.88% | -67.88% |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | -165.57% | -146.09% | 30.63% | 465.14% |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | -2.13% | -45.09% | -61.80% | -44.27% |
| Seer, Inc. (SEER)vs › | $120.41M | -30.12% | -27.41% | -24.34% | -19.85% |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | -234.42% | -102.69% | -100.55% | -100.92% |
| Cibus, Inc. (CBUS)vs › | $119.84M | -663.38% | -427.48% | -294.92% | -251.31% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -57.47% | -26.63% | 16.73% | 210.40% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | -148.56% | -96.59% | -83.25% | -64.44% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -61.33% | -137.84% | -101.43% | -77.25% |
ROE
-5.1%
ROA
-4.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-09-30 | -5.10% |
| 2024-09-30 | -3.38% |
| 2023-09-30 | -18.18% |
| 2022-09-30 | 2.03% |
| 2021-09-30 | 5.75% |
| 2020-09-30 | 19.40% |
| 2019-09-30 | 26.80% |
| 2018-09-30 | 33.74% |
| 2017-09-30 | 12.58% |
